{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:33:13Z","timestamp":1794475993331,"version":"4.9.1"},"reference-count":32,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3751,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00564.x","type":"journal-article","created":{"date-parts":[[2005,5,25]],"date-time":"2005-05-25T15:37:28Z","timestamp":1117035448000},"page":"665-671","source":"Crossref","is-referenced-by-count":22,"title":["A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease"],"prefix":"10.1155","volume":"59","author":[{"given":"A.","family":"Norman Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bergheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Fagertun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Moum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2005,5,25]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB1|cit1","unstructured":"National Institute for Clinical Excellence 2000 Guidance on the Use of Proton Pump Inhibitors (Ppis) in the Treatment of Dyspepsia . http:\/\/www.nice.org.uk"},{"issue":"(Suppl. 1)","key":"10.1111\/j.1368-5031.2005.00564.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000200911","article-title":"Epidemiology and natural history of gastro-oesophageal reflux disease","volume":"51","author":"Spechler","year":"1992","journal-title":"Digestion"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/pgmj.74.869.145","article-title":"Trends in the management of gastro-oesophageal reflux disease","volume":"74","author":"Lee","year":"1998","journal-title":"Postgrad Med J"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2036.1997.00181.x","article-title":"Review article. current practice and future perspectives in the management of gastro-oesophageal reflux disease","volume":"11","author":"Lambert","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3109\/00365529709011211","article-title":"Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice","volume":"32","author":"Venables","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/13814789509161628","article-title":"Gastro-oesophageal reflux disease in primary care in Europe","volume":"1","author":"Jones","year":"1995","journal-title":"Eur J Gen Pract"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3109\/00365528709011148","article-title":"Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease","volume":"22","author":"Johnssen","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3109\/00365529709011212","article-title":"Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response","volume":"32","author":"Lind","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-199802000-00004","article-title":"Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole","volume":"10","author":"Carlsson","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00564.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2036.1997.tb00798.x","article-title":"Endoscopy-negative acid reflux disease","volume":"11","author":"Smout","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1365-2036.1997.00185.x","article-title":"Treating the symptoms of gastro-oesophageal reflux disease. a double-blind comparison of omeprazole and cisapride","volume":"11","author":"Galmiche","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00564.x-BIB12|cit12","first-page":"S5","article-title":"Reflux disease: the disorder of the third millennium","volume":"13","author":"Holtmann","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB13|cit13","first-page":"19","article-title":"Quality of life during acute and intermittent treatment of gastroesophageal reflux disease with omeprazole compared with ranitidine. Results from a multi-center clinical trial","volume":"30","author":"Wiklund","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/dote\/10.1.9","article-title":"The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis","volume":"10","author":"Tew","year":"1997","journal-title":"Dis Esophagus"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1365-2036.1997.144320000.x","article-title":"Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis","volume":"11","author":"Hatlebakk","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00564.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.44.2008.S1","article-title":"on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management - the Genval Workshop Report","volume":"44","author":"Dent","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB17|cit17","first-page":"1749","article-title":"Efficacy and safety of lansoprazole in the treatment of erosive reflux oesophagitis","volume":"91","author":"Castell","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2036.1995.tb00437.x","article-title":"Pantoprazole and omeprazole in the treatment of reflux esophagitis: a European multicentre study","volume":"9","author":"Corinaldesi","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0016-5085(94)90531-2","article-title":"Omeprazole or ranitidine in long-term treatment of reflux esophagitis","volume":"107","author":"Hallerb\u00e4ck","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2036.1995.tb00388.x","article-title":"A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: a multicentre trial","volume":"9","author":"M\u00f6ssner","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB21|cit21","unstructured":"Moore RA Wiffen P McQuay HJ Phillips C. http:\/\/www.jr2.ox.ac.uk\/bandolier\/bandopubs\/gordf\/gord.html"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB22|cit22","first-page":"311","article-title":"Gastro-oesophageal reflux disease","volume":"5","author":"Moayyedi","year":"2001","journal-title":"Clin Evid"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2036.2000.00813.x","article-title":"Esomeprazole provides improved acid control vs. Omeprazole in patients with symptoms of gastro-oesophageal reflux disease","volume":"14","author":"Lind","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00564.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"A20","DOI":"10.1016\/S0016-5085(00)82149-6","article-title":"Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg","volume":"118","author":"R\u00f6hss","year":"2000","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00564.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"A22","DOI":"10.1016\/S0016-5085(00)82157-5","article-title":"Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg","volume":"118","author":"Wilder-Smith","year":"2000","journal-title":"Gastroenterology"},{"issue":"Suppl. 9","key":"10.1111\/j.1368-5031.2005.00564.x-BIB26|cit26","first-page":"S44","article-title":"Esomeprazole 40 mg provides more effective acid control than lansoprazole 15 mg. American Journal of","volume":"96","author":"Wilder-Smith","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB30|cit30","first-page":"A199","article-title":"Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed erosive esophagitis","volume":"122","author":"Lind","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","article-title":"Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of \u2018on-demand\u2019 therapy for 6 months","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1368-5031.2005.00564.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200208000-00008","article-title":"Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease - a placebo-controlled trial of \u2018on-demand\u2019 therapy for 6 months","volume":"14","author":"Talley","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00564.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00564.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T03:27:38Z","timestamp":1706239658000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00564.x"}},"subtitle":["Esomeprazole: Managing Symptoms of Gerd"],"short-title":[],"issued":{"date-parts":[[2005,5,25]]},"references-count":32,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00564.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5,25]]}}}